Smilax Laboratories

What Smilax Laboratories does

Smilax Laboratories Limited is a fully backward-integrated Active Pharmaceutical Ingredient (API) manufacturer serving the global generics market across more than 60 countries. Founded in 2004 and promoted by the US$2 billion Ramky Group, the company is headquartered in Hyderabad, India, and operates two multi-product cGMP manufacturing facilities in Hyderabad (Telangana) and Visakhapatnam (Andhra Pradesh) with a combined built-up area of 370,000 SFT and current multipurpose capacity of 475 KL, with publicly stated plans to scale to 1,200 KL. Its technology stack is anchored in classical pharmaceutical chemistry: catalytic hydrogenations, cyanation, Grignard reactions, halogenations, nitrations, Friedel-Krafts reactions, chiral separations, and polymorphic form studies, complemented by continuous manufacturing and high-potency API production capabilities. A 60+ scientist R&D Centre focuses on complex API synthesis and non-infringing process development.

The company's product portfolio spans four lines: (1) APIs covering antihypertensives, antiulceratives, antifungals, antipsychotics, antidepressants and other therapeutic categories including Amlodipine Besylate, Clopidogrel Bisulfate, Esomeprazole Mg, and Itraconazole; (2) API Intermediates for molecules such as Apixaban, Dabigatran, Rivaroxaban, Valsartan, and Saxagliptin; (3) Pellets and DC Granules including Immediate, Sustained, Extended, and Modified Release formulations and MUPS at a dedicated 1,200 MT annual-capacity Visakhapatnam facility; and (4) CDMO/CMO services covering R&D, process optimization, trial batch manufacturing, regulatory support (DMF, CMC), technology transfer, and commercial-scale production. Regulatory approvals include USFDA (Unit-I 2015, Unit-IV 2023), EU-GMP from OGYEI Hungary (2020), PMDA Japan (Unit-IV 2023, Unit-I 2024), and WHO-GMP for both units.

Smilax generates revenue through direct B2B enterprise sales of API products and contract development/manufacturing services to global generics pharmaceutical companies in regulated markets (USA, Europe, Japan) and emerging markets. Pricing is quote-based and not publicly disclosed. The GTM motion is enterprise field sales supported by a corporate website with product-specific inquiry forms (API, Intermediates, Pellets, DC Granules, Certifications, R&D, Careers). The company has received the Government of India's 'Outstanding Exports Award' in the Bulk Drugs category for three consecutive years. Detailed revenue, customer concentration, and ownership data are not publicly disclosed.

Name

Smilax Laboratories

Legal name

Smilax Laboratories Limited

Website

https://smilaxlabs.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

Smilax Laboratories Limited is a backward-integrated Active Pharmaceutical Ingredient manufacturer serving the global generics market across 60+ countries. Founded in 2004 and promoted by the US$2 billion Ramky Group, it produces APIs, intermediates, pellets, and CDMO services from USFDA/EU-GMP/PMDA-approved facilities in Hyderabad and Visakhapatnam, India.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• API intermediates
• Generic drug formulations
• Contract manufacturing services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. API Manufacturing and Sales: Manufacturing and sale of Active Pharmaceutical Ingredients for generic drug formulations. Revenue generated through product sales to pharmaceutical companies worldwide. Fully backward integrated operations covering API intermediates to finished APIs.
2. CDMO Services: Contract Development and Manufacturing Organization services spanning the drug development lifecycle including R&D, process optimization, trial batch manufacturing, regulatory support, technology transfer, and commercial-scale production for client APIs.
3. CMO Services: Contract Manufacturing Organization services for API production from trial batches to commercial scale, providing cost-effective manufacturing with regulatory compliance support.
4. Pellets and DC Granules: Manufacturing and sale of specialized drug delivery systems including Immediate Release, Sustained Release, Extended Release, Modified Release Pellets, Blended Pellets, Pre-mixes, MUPS, and DC Granules.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Smilax Laboratories Limited is a fully backward integrated Active Pharmaceutical Ingredients (API) manufacturer catering to the global generics market. The company produces APIs, API intermediates, and Novel Drug Delivery System (NDDS) pellets/DC granules from cGMP-compliant manufacturing facilities in Hyderabad and Visakhapatnam, India, and also offers Contract Development and Manufacturing Organization (CDMO/CMO) services spanning R&D through commercial-scale production.

Product overview

Smilax Laboratories is a fully backward integrated Active Pharmaceutical Ingredients manufacturing company offering a portfolio of high-quality and difficult-to-make pharmaceutical products for the generics market. The company's product portfolio comprises four main offerings: (1) Active Pharmaceutical Ingredients covering multiple therapeutic categories such as antihypertensives, antiulceratives, antifungals, and antidepressants; (2) API Intermediates providing key synthesis intermediates for drugs like Apixaban, Dabigatran, and Valsartan; (3) Pellets and DC Granules encompassing Novel Drug Delivery Systems including Immediate Release, Sustained Release, and Extended Release pellets; and (4) CDMO and CMO services providing contract research, development, and manufacturing capabilities. The company operates manufacturing facilities at Hyderabad and Visakhapatnam with regulatory approvals from USFDA, EU-GMP, and PMDA Japan.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs)

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cambrex: US/EU small-molecule API CDMO with strong positions in controlled substances, high-potency APIs, and complex chemistry. Comparable technology stack (high-potency, continuous manufacturing) and CDMO service layer targeting innovator and generic customers.
• Divi's Laboratories: India-based, fully backward-integrated small-molecule API manufacturer serving the global generics market with significant CDMO exposure (custom synthesis for innovator pharma). Directly comparable to Smilax on API manufacturing, intermediates, and contract development services for regulated markets.
• Laurus Labs: Indian API manufacturer with integrated contract development and manufacturing services targeting regulated generic and innovator markets. Closely comparable on API/intermediates + CDMO mix, USFDA-inspected facilities, and global commercial reach.
• Hovione: Portugal-headquartered CDMO with strong small-molecule API and intermediates capabilities, serving innovator pharma on complex chemistry. Comparable on CDMO service layer and high-potency/continuous-manufacturing technology that Smilax now offers.
• Granules India: Indian manufacturer focused on API intermediates, APIs, and pellets/DC granules — overlapping directly with Smilax's Pellets and DC Granules business (IR/SR/ER pellets, MUPS). Comparable on novel drug delivery systems and generic supply to global customers.
• Neuland Laboratories: Hyderabad-headquartered small-molecule API and intermediates manufacturer offering contract development and manufacturing services. Similar scale, technology stack (complex synthesis, chiral chemistry), and customer profile in regulated generics APIs.
• Shilpa Medicare: Indian API, intermediates, and formulation manufacturer with growing CDMO business and multi-regulatory approvals. Comparable scale and technology mix, including complex API synthesis and backward integration.
• MSN Laboratories: Indian API manufacturer with backward integration into intermediates and finished dosage forms, supplying USFDA, EU-GMP, and PMDA-regulated markets. Direct peer on therapeutic categories (cardiovascular, CNS, anti-infectives) and customer mix.

Broad incumbents

• Aurobindo Pharma: Much larger vertically integrated Indian pharmaceutical company with API and finished-dose generics. Sits on Smilax's customer/supplier value chain — competes on select APIs while also being a major buyer of intermediates in the Indian ecosystem.
• Dr. Reddy's Laboratories: Large Indian integrated pharmaceutical company with API, finished-dose, and biosimilars businesses supplying USA, Europe, and emerging markets. Comparable on regulated-market generics API supply though at materially greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/smilaxlabs
• LinkedInlinkedin.com/company/smilax-laboratories-limited

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Smilax Laboratories